Daan De Maeseneer
Overview
Explore the profile of Daan De Maeseneer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verghote F, Rammant E, Dirix P, Van Praet C, Berghen C, Junius S, et al.
Eur Urol Focus
. 2025 Feb;
PMID: 39971695
Background And Objective: Patients with muscle-invasive bladder cancer (MIBC) who develop a recurrence after radical cystectomy (RC) have poor outcomes. This study aims to evaluate the safety and efficacy of...
2.
De Maeseneer D, De Visschere P, Van den Broecke M, Delbare F, Villeirs G, Verbeke S, et al.
BMC Med Imaging
. 2024 Oct;
24(1):268.
PMID: 39375642
Background: Muscle invasive bladder cancer (MIBC) treatment combines systemic therapy and radical cystectomy (RC) or local (chemo-)radiotherapy. Response to systemic therapy is an important outcome predictor but is difficult to...
3.
Franco A, Tailly T, Berquin C, De Maeseneer D, Decruyenaere A, Verbeke S, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102202.
PMID: 39288545
Medullary sponge kidney (MSK) is an uncommon kidney malformation, characterized by cystic dilatation of the precalyceal papillary collecting ducts. Urography and computed tomography scan represent the gold standard to detect...
4.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al.
Nat Med
. 2024 Aug;
30(11):3381.
PMID: 39198712
No abstract available.
5.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al.
Nat Med
. 2024 Aug;
30(11):3291-3302.
PMID: 39164518
ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian framework to evaluate efficacy within predefined biomarker signatures across systemic treatments. Prospective circulating tumor DNA and germline...
6.
Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F, et al.
JAMA Oncol
. 2023 Jul;
9(9):1205-1213.
PMID: 37410476
Importance: Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to...
7.
Verghote F, Van Praet C, De Maeseneer D, Berquin C, Vanneste B, De Visschere P, et al.
Cancer Manag Res
. 2023 Jun;
15:511-521.
PMID: 37337479
Purpose: Pronounced underuse of radiotherapy (RT) in muscle-invasive bladder cancer (MIBC) is reported. This study aims to assess the awareness about the role of RT in different MIBC settings and...
8.
Lambert E, Lumen N, Fonteyne V, De Maeseneer D, Verbeke S, Villeirs G, et al.
Clin Genitourin Cancer
. 2022 Dec;
21(3):415.e1-415.e8.
PMID: 36529628
Introduction: To describe the changes in systemic treatments (ST) of synchronous metastatic hormone-sensitive prostate cancer (mHSPC) patients in a "real-world" setting and to explore reasons why contemporary standard of care...
9.
Vergote I, Van Nieuwenhuysen E, De Waele S, Vulsteke C, Lamot C, Van den Bulck H, et al.
Int J Gynecol Cancer
. 2022 Jan;
32(6):753-760.
PMID: 35063943
Objective: Because elderly patients with ovarian cancer are underrepresented in randomized studies, this study aimed to expand our knowledge on the safety and effectiveness of frontline treatment with bevacizumab in...
10.
Verghote F, Poppe L, Verbeke S, Dirix P, Albersen M, De Meerleer G, et al.
BMC Cancer
. 2021 Oct;
21(1):1113.
PMID: 34663254
Background: The outcome of patients with muscle-invasive bladder cancer (MIBC) remains poor, despite aggressive treatments. Inadequate primary staging, classically performed by computed tomography (CT)-imaging, could lead to inappropriate treatment and...